Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus LOTEPREDNOL ETABONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus LOTEPREDNOL ETABONATE.
DEXACORT vs LOTEPREDNOL ETABONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid